Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm Registration Study to Evaluate Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

Next Previous
X
Search
Trial Profile

A Single-Arm Registration Study to Evaluate Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upifitamab rilsodotin (Primary)
  • Indications Ovarian cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms UPLIFT
  • Sponsors Mersana Therapeutics

    • Most Recent Events

    • 07 Nov 2023 According to a Mersana Therapeutic media release, the company plans to share detailed efficacy and safety data with the medical and scientific community in the first half of 2024.
    • 27 Jul 2023 Primary endpoint (Objective response rate (ORR) in the higher NaPi2b patient population) has not been met, according to a Mersana Therapeutics media release.
    • 27 Jul 2023 Results presented in the Mersana Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top